文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

远端恶性胆道梗阻置入覆膜自膨式金属支架后胆囊炎的系统评价与荟萃分析

Postprocedural cholecystitis following covered self-expandable metal stent placement in patients with distal malignant biliary obstruction: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2025-07-01

结果显示覆膜支架组ERCP后急性胆囊炎发生率和支架移位率更高,肿瘤长入率更低;胆囊原位亚组分析结果一致。

要点

  • 覆膜支架较未覆膜支架增加ERCP后急性胆囊炎风险(RR 1.71)。
  • 覆膜支架肿瘤长入率显著更低(RR 0.13),但支架移位率更高(RR 7.53)。
  • 胆囊原位患者选择支架时应权衡胆囊炎风险。

核心结论

  • 覆膜自膨式金属支架置入后ERCP后胆囊炎发生率高于未覆膜支架。
  • 研究提示应谨慎选择支架,尤其对胆囊原位患者,以减少不良事件并避免肿瘤治疗延迟。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase、SCOPUS和Cochrane Library截至2024年12月的文献。
  • 采用随机效应模型计算合并相对危险度(RR)及95%CI,并按研究设计和胆囊原位状态进行亚组分析。

主要发现

  • 覆膜支架组ERCP后急性胆囊炎发生率高于未覆膜支架组(RR 1.71;95%CI 1.12-2.62)。
  • 覆膜支架组肿瘤长入率低于未覆膜支架组(RR 0.13;95%CI 0.06-0.25)。
  • 覆膜支架组支架移位率高于未覆膜支架组(RR 7.53;95%CI 4.60-12.32)。
  • 基于胆囊原位的亚组分析同样显示上述差异。

临床怎么用

  • 远端恶性胆道梗阻行ERCP支架置入时,应权衡覆膜支架的胆囊炎与移位风险及较低的肿瘤长入风险。
  • 对胆囊原位患者,支架选择需个体化,以优化患者管理并减少不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Incidence of postprocedural cholecystitis after ERCP using a covered self-expandable metal stent (CSEMS) for distal malignant biliary obstruction (MBO) has been gradually reported. Without sufficient data, the recommendation for stent placement favors CSEMSs over uncovered self-expandable metal stents (USEMSs), with the tip placed below the cystic duct orifice. This study assessed the safety of CSEMSs versus USEMSs in the management of distal MBO. METHODS: All studies published up to December 2024 comparing adverse events after CSEMS and USEMS placement for biliary drainage were identified using PubMed, Embase, SCOPUS, and the Cochrane Library. Outcomes of interest were postprocedural cholecystitis, pancreatitis, stent migration, and tumor ingrowth. Pooled relative risks (RRs) with 95% CIs were calculated using a random-effect model. Subgroup analyses were performed based on study design and the presence of a gallbladder in situ. RESULTS: Twenty-one studies (5753 patients) met inclusion criteria. The CSEMS group showed higher post-ERCP acute cholecystitis rates (RR, 1.71; 95% CI, 1.12-2.62), lower tumor in growth rates (RR, 0.13; 95% CI, 0.06-0.25), and higher rates of stent migration (RR, 7.53; 95% CI, 4.60-12.32). The difference was also demonstrated in subgroup analysis based on the presence of a gallbladder in situ. CONCLUSIONS: Our study demonstrated higher rates of postprocedural cholecystitis following ERCP with CSEMS placement compared with USEMS placement. These findings highlight the importance of careful stent selection, particularly in patients with gallbladder in situ, to optimize patient care, reduce adverse events, and prevent delays in oncologic management.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Lopimpisuth C, Vedantam S, Danpanichkul P, et al. Postprocedural cholecystitis following covered self-expandable metal stent placement in patients with distal malignant biliary obstruction: a systematic review and meta-analysis. Gastrointest Endosc. 2025. PMID: 40602730. doi:10.1016/j.gie.2025.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。